The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Apr. 20, 2021

Filed:

Jan. 18, 2019
Applicants:

Beijing Dongfang Biotech Co., Ltd., Beijing, CN;

Beijing Jingyitaixiang Technology Development Co., Ltd., Beijing, CN;

Inventors:

Haiping Zhou, Beijing, CN;

Xiaomin Li, Beijing, CN;

Junjie Zhou, Beijing, CN;

Shuang Pei, Beijing, CN;

Yanlu Zan, Beijing, CN;

Yi Bai, Beijing, CN;

Xianhong Bai, Beijing, CN;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61K 47/68 (2017.01);
U.S. Cl.
CPC ...
C07K 16/2818 (2013.01); A61K 47/6803 (2017.08); A61K 47/6849 (2017.08); C07K 2317/21 (2013.01); C07K 2317/31 (2013.01); C07K 2317/565 (2013.01); C07K 2317/622 (2013.01); C07K 2317/76 (2013.01); C07K 2317/92 (2013.01);
Abstract

The invention provides human monoclonal antibodies that specifically bind to PD-1 with high affinity. The anti-PD-1 monoclonal antibodies were screened from a synthetic antibody library, and affinity maturation was performed. The synthetic antibody libraries used to select for the high affinity anti-PD-1 monoclonal antibodies were made by replacing the light chain CDR1, CDR2 and CDR3 and heavy chain CDR1, CDR 2 and CDR 3 of phage libraries from the preliminary screening, and the high affinity anti-PD-1 monoclonal antibodies were selected. The human anti-PD-1 monoclonal antibodies have high affinity and inhibit the binding of PD-1 to its ligand PD-L1. The antibodies can be used for treating tumor, inflammation and autoimmune diseases.


Find Patent Forward Citations

Loading…